PMV Pharmaceuticals, Inc. (PMVP)
After hours:
| Previous close | 8.16 |
| Open | 8.16 |
| Bid | 8.16 x 800 |
| Ask | 9.51 x 800 |
| Day's range | 8.16 - 8.31 |
| 52-week range | 7.57 - 24.26 |
| Volume | |
| Avg. volume | 540,972 |
| Market cap | 374.456M |
| Beta (5Y monthly) | 1.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.43 |
| Earnings date | 27 Feb 2023 - 03 Mar 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 26.17 |
- Zacks
Does PMV Pharmaceuticals, Inc. (PMVP) Have the Potential to Rally 267% as Wall Street Analysts Expect?
The mean of analysts' price targets for PMV Pharmaceuticals, Inc. (PMVP) points to a 267.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- GlobeNewswire
PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
CRANBURY, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President & Chief Executive Officer of PMV Pharmaceuticals, will participate in a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference, taking place November 29 – December 1, 2022. The company will al
- GlobeNewswire
PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights
Enrollment continued in the Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation Phase 1b combination trial with Merck evaluating PC14586 with KEYTRUDA® (pembrolizumab) on track to initiate in 2022 Biotech industry veteran Dr. Carol Gallagher appointed to Board of Directors CRANBURY, N.J., Nov. 08, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology com
